Comparable long-term effectiveness to standard of care corticosteroids over 5 years Normal growth maintained, in contrast to growth suppression ...

Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that 12 abstracts have been accepted for presentation at ...

Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. ("Pharming” or "the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that 12 abstracts have been accepted for presentation at ...

JADE101 is an investigational,potentially best-in-class disease-modifyinganti-APRIL monoclonal antibody, with a Phase 1 healthy volunteer study underway SAN FRANCISCO and VANCOUVER, British Columbia, ...

The Texas-based company announced on Tuesday that its research collaborators will present preclinical data at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer ...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that five posters will be presented in collaboration with independent investigators highlighting new data on LUPKYNIS ® (voclosporin) at the ...

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...